Anti-Human IL-12/IL-23 p40 Reference Antibody (Briakinumab, RUO)

Description: Research Grade Briakinumab (BS10010) is a human monoclonal antibody detecting IL-12 subunit p40 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human.
Highlights:
• Multi-Application — Validated across multiple applications.
Host species: Human
Isotype: IgG1-lambda
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1.68mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: IL-12 subunit p40, IL12B, Interleukin-12 subunit beta, IL-12B, CLMF p40, NKSF2, NK cell stimulatory factor chain 2, Cytotoxic lymphocyte maturation factor 40k Da subunit
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: ABT-874, J695, CAS:339308-60-0
Background: Interleukin-12 subunit beta (IL-12 subunit p40,IL12B,Interleukin-12 subunit beta,IL-12B,CLMF p40,NKSF2,NK cell stimulatory factor chain 2,Cytotoxic lymphocyte maturation factor 40 kDa subunit) is a ~37 kDa protein. Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC.
Note: For research use only. Not suitable for clinical or therapeutic use.